Tracey Walker, Contributing Editor
Progress in cancer treatment continues to surge
With U.S. life expectancy for people with cancer at an all-time high, life-years saved now surpass 50 million.
FDA approves the first generic versions of depression drug Cymbalta
Aurobindo, Dr. Reddy’s, Lupin, Sun Pharma, Teva, and Torrent Pharmaceuticals all received the OK.
CVS Caremark and Cardinal Health team up to supply generic drugs
WAG–Boots–Amerisource Bergen was only the first. Here comes another behemoth.
Metformin improves outcomes for cancer patients with type 2 diabetes
In cancer patients with concurrent type 2 diabetes, metformin alone or in combination with other regimens was associated with 34% reduction in overall death risk and 38% reduction in cancer-specific death risk, according to a study in the December issue of The Oncologist.
Anti-diabetic drugs can lower cancer risk by 32%
A specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes up to 32%, according to a study published in Diabetes, Obesity and Metabolism. People with type 2 diabetes have a higher rate of cancer development and recurrence compared to the general population.
Simeprevir approved for hepatitis C virus
FDA has approved simeprevir (Olysio, Janssen Therapeutics) for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.
Muscle pain that turns off statin users can result from interactions with other drugs
Patients who quit taking their statins are frequently on 3-4 other meds as well, and drug interactions are amplifying their experience of muscle pain.
FDA lifts some restrictions on diabetes drug Avandia
Reevaluation of RECORD trial data fails to uncover elevated cardiovascular risk.
FDA warns of MI with cardiac nuclear stress test agents
FDA is warning healthcare professionals of the rare but serious risk of heart attack and death with use of cardiac nuclear stress test agents regadenoson (Lexiscan) and adenosine (Adenoscan).
FDA approves rare blood cancer drug under breakthrough therapy designation
FDA has approved ibrutinib (Imbruvica, Pharmacyclics and Janssen) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. It is the second drug with breakthrough therapy designation to receive FDA approval.


View Results